- Home
- ALKT vs ADPT Comparison
ALKT vs ADPT Comparison
Compare ALKT & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALKT
- ADPT
- Stock Information
- Founded
- ALKT 2007
- ADPT 2009
- Country
- ALKT United States
- ADPT United States
- Employees
- ALKT N/A
- ADPT N/A
- Industry
- ALKT EDP Services
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALKT Technology
- ADPT Health Care
- Exchange
- ALKT Nasdaq
- ADPT Nasdaq
- Market Cap
- ALKT 2.6B
- ADPT 2.6B
- IPO Year
- ALKT 2021
- ADPT 2019
- Fundamental
- Price
- ALKT $21.31
- ADPT $19.62
- Analyst Decision
- ALKT Buy
- ADPT Strong Buy
- Analyst Count
- ALKT 8
- ADPT 10
- Target Price
- ALKT $35.88
- ADPT $16.60
- AVG Volume (30 Days)
- ALKT 1.9M
- ADPT 2.4M
- Earning Date
- ALKT 10-30-2025
- ADPT 11-05-2025
- Dividend Yield
- ALKT N/A
- ADPT N/A
- EPS Growth
- ALKT N/A
- ADPT N/A
- EPS
- ALKT N/A
- ADPT N/A
- Revenue
- ALKT $412,504,000.00
- ADPT $252,754,000.00
- Revenue This Year
- ALKT $35.49
- ADPT $36.43
- Revenue Next Year
- ALKT $23.99
- ADPT $12.31
- P/E Ratio
- ALKT N/A
- ADPT N/A
- Revenue Growth
- ALKT 30.72
- ADPT 42.57
- 52 Week Low
- ALKT $18.71
- ADPT $5.29
- 52 Week High
- ALKT $41.77
- ADPT $20.76
- Technical
- Relative Strength Index (RSI)
- ALKT 49.26
- ADPT 67.55
- Support Level
- ALKT $20.76
- ADPT $13.28
- Resistance Level
- ALKT $21.86
- ADPT $20.76
- Average True Range (ATR)
- ALKT 0.85
- ADPT 1.12
- MACD
- ALKT 0.28
- ADPT 0.58
- Stochastic Oscillator
- ALKT 81.36
- ADPT 84.89
About ALKT Alkami Technology Inc.
Alkami Technology Inc is a cloud-based digital banking solutions provider. The company's solution, the Alkami Digital Banking Platform, allows FIs to onboard and engage new users, accelerate revenues and meaningfully improve operational efficiency, all with the support of a proprietary, true cloud-based, multi-tenant architecture.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).